exRNAdisease

General Information

Database ID:

exR0077413

RNA Name:

NACC1

RNA Type:

mRNA

Chromosome:

chr19

Starnd:

Coordinate:

Start Site(bp):

13116862

End Site(bp):

13141147

External Links:

Disease Information

Disease Name:	Fragile X Syndrome
Disease Category:	Congenital, Hereditary, and Neonatal Diseases and Abnormalities
MeSH ID:	D005600
Type:	Diseases Category/Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Alias:	Fragile X Syndromes//Syndrome, Fragile X//Syndromes, Fragile X//Marker X Syndrome//Marker X Syndromes//Syndrome, Marker X//Syndromes, Marker X//Mental Retardation, X-Linked, Associated With Marxq28//X-Linked Mental Retardation and Macroorchidism//X Linked Mental Retardation and Macroorchidism//Fragile X Mental Retardation Syndrome//Martin-Bell Syndrome//Martin Bell Syndrome//Syndrome, Martin-Bell//Fra(X) Syndrome//FRAXE Syndrome//FRAXE Syndromes//Syndrome, FRAXE//Syndromes, FRAXE//Mental Retardation, X-Linked, Associated With Fragile Site Fraxe//Fragile X-F Mental Retardation Syndrome//Mar (X) Syndrome//FRAXA Syndrome//FRAXA Syndromes//Syndrome, FRAXA//Syndromes, FRAXA

Expression Detail

GEO ID:	GSE83556
Description:	Global transcriptome dysregulation in second trimester fetuses with FMR1 expansions
Experimental Design:	Disease vs Control
Case Disease Type:	Fragile X Syndrome
Case Disease SubType:	NA
Case Sample:	Fragile X Syndrome
Control Sample:	Normal
Number of Case:	22
Number of Control:	18
Number of Samples:	40

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AAGAB	chr15	67200667	67255195	-
ABCF1	chr6	30571393	30597179	+
AC005726.1	chr17	28455752	28614185	-
AC011511.1	chr19	10305427	10316009	-
AC099811.2	chr17	42119674	42154916	-
ACACA	chr17	37084992	37406836	-
AEBP2	chr12	19404045	19720801	+
AGAP6	chr10	49982190	50010499	+
AHSA1	chr14	77457870	77469472	+
AL117348.2	chr1	225886696	225924278	-

miRNA targets:

miRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa-miR-103a-3p	chr5	168560904	168560926	-
hsa-miR-107	chr10	89592756	89592778	-
hsa-miR-185-5p	chr22	20033153	20033174	+
hsa-miR-331-3p	chr12	95308480	95308500	+
hsa-miR-324-3p	chr17	7223308	7223330	-
hsa-miR-346	chr10	86264747	86264769	-
hsa-miR-663a	chr20	26208243	26208264	-
hsa-miR-671-5p	chr7	151238449	151238471	+
hsa-miR-361-3p	chrX	85903641	85903663	-
hsa-miR-362-3p	chrX	50009005	50009026	+
hsa-miR-423-5p	chr17	30117095	30117117	+
hsa-miR-541-3p	chr14	101064548	101064569	+
hsa-miR-1294	chr5	154347153	154347174	+
hsa-miR-1270	chr19	20399320	20399342	-
hsa-miR-1307-3p	chr10	103394301	103394322	-

circRNA targets:

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC002470.2	chr22	20979462	20998121	+
AC018521.1	chr17	47945424	47981736	+
AD000090.1	chr19	35557956	35581954	+

Display:

Experiment Detail

GEO ID:	GSE83556
Sample Source:	Amniotic Fluid
Source Fraction:	Supernatant
Platform:	GPL570
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	17063
Sample treatment protocol:	RNA was extracted from 5-15 mL amniotic fluid supernatant (centrifugation at 350g, 4C, 10, min).
RNA Extract protocol:	All samples were processed using the Qiagen Circulating Nucleic Acid kit with an on-column DNase digestion step to remove genomic DNA. The RNA was then purified and concentrated with the RNeasy MinElute Clean up kit and eluted in RNasefree water.
RNA library preparation protocol:	RNA was converted to cDNA and amplified using the Ovation Pico WTA kit V2 and then purified with the QIAquick PCR Purification kit. Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA)Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA).

Reference